BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17283145)

  • 1. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
    Holtz M; Forman SJ; Bhatia R
    Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
    Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS; Forman SJ; Bhatia R
    Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
    Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
    Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R
    Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
    Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
    Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
    Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
    Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
    Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
    Konig H; Holtz M; Modi H; Manley P; Holyoake TL; Forman SJ; Bhatia R
    Leukemia; 2008 Apr; 22(4):748-55. PubMed ID: 18273048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.